"Men"

An obvious feature of autumn that is different from summer is that the temperature drops, the weather is unpredictable, and the temperature difference between morning and night is large, which has become one of the main causes of female biological clock disorder, endocrine disorder and bacterial infection in autumn. In addition, the resistance of the human body decreases relatively in autumn, which is also a time of high recurrence for patients with gynecological diseases.

There are many diseases that may recur after treatment, so many head and neck cancer patients are worried about such a situation, and their frequent ruminations may cause a lot of psychological stress to them.

There is an urgent clinical need for new antimicrobial drugs to break through the dilemma of cIAI treatment in children and address the growing challenge of drug resistance.

The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours

Anemia is a very common problem among women. Anemia makes people less resistant and depressed, and serious anemia can also endanger the health of the body, so when the situation of anemia occurs, it should be promptly adjusted. The actual fact is that you will be able to get a lot more than just a few of the most popular and popular items.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Brigham and Women's Hospital (formerly Brigham and Women's Hospital), also known as Brigham and Women's Hospital, has a long history and is the second largest hospital affiliated with Harvard Medical School in the United States. Hospital (founded in 1832), which merged in 1980

Approval for new FIC depression drug on the horizon!

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Leukaemia is a very complex disease that causes fever and infection and bleeding, so it needs to be treated early so that it can be gradually controlled and the patient's symptoms can be gradually relieved